Drug Trial Radar · NCT07543458
Therapeutics for Moderate and Severe Dengue
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
8,800
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Jul 31, 2030
Study completion Jul 31, 2031
Sponsor
- Lead sponsor
- Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Oxford; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Number 2 Children's Hospital, Ho Chi Minh City; Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal; National Academy of Medical Sciences/Bir Hospital, Kathmandu, Nepal; Siriraj Hospital; Prince of Songkla University in Southern Thailand, Thailand; Dhaka Medical College; Chittagong Medical College and Hospital; Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia; Hospital Universitario Erasmo Meoz, Cucuta, Colombia; Fundación Valle del Lili, Cali, Colombia; Hospital Regional de Loreto, Iquitos, Peru; Instituto de Infectologia Emílio Ribas, São Paulo, Brazil; Universitas Sumatera Utara; Universitas Airlangga; University of Malaya; Hospital Queen Elizabeth, Malaysia; San Lazaro Hospital (SLH-NU), Manila, Philippines
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.
Conditions
- Dengue
- Severe Dengue
- Mosquito-Borne Diseases
- Vector Borne Diseases
- Arbovirus Infections
- Flavivirus Infections
- RNA Virus Infections
- Hemorrhagic Fever
Interventions
PlaceboDrug
Placebo matched to baricitinib/dexamethasone in form, dose, frequency and duration.
DexamethasoneDrug
Dexamethasone is a corticosteroid. Form: tablet or intravenous preparation. Dose: Aged ≥ 12 years: 6mg once daily. Aged 5 - 11 years by weight: * 10kg to \<20 kg: 2mg once daily, * 20kg to \<30 kg: 4mg once daily, * 30kg: 6mg once daily. Duration: 4 days, or until discharge if this happens before.
N-AcetylcysteineDrug
N-acetylcysteine acts to protect the liver. It functions as a glutathione precursor and antioxidant. Dose: 100mg/kg/day, by continuous infusion over 24 hours in glucose 5% (preferred) or sodium chloride 0.9%. Duration: 4 days, or until hospital discharge if sooner.
Standard of careOther
Standard of care as per local site guidelines
BaricitinibDrug
Baricitinib is an inhibitor of Janus Kinase (JAK) 1 \& 2, and Numb associated kinase (NAK). Form: tablet. Dose: Aged ≥ 12 years: 4mg once daily, Aged 5 - 11 years: 2mg once daily. - Renal adjustment of dose: Adults: eGFR ≥30 and \<60 mL/min/1.73m2: 2mg once daily, eGFR ≥15 and \<30 mL/min/1.73m2: 2mg on alternate days. Children: eGFR ≥30 and \<60mL/min/1.73m2: 2mg on alternate days \- Dose should be halved in patients also taking probenecid Duration: 4 days, or less if the patient is discharged before this time.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression to severe dengue/critical dengueTime frame: between randomization to hospital discharge (average of 5 days)
- All-cause mortality within 30 daysTime frame: Day 30
Locations
18 sites in 10 countries. Site status is shown where the registry gives one.
Chittagong Medical College Hospital
Chittagong, Bangladesh
Dhaka Medical College & Hospital
Dhaka, Bangladesh
Dhaka North City Corporation Hospital
Dhaka, Bangladesh
Instituto de Infectologia Emílio Ribas
São Paulo, Brazil
Centro de Atención y Diagnóstico de Enfermedades Infecciosas
Bucaramanga, Colombia
Fundación Valle del Lili
Cali, Colombia
Hospital Universitario Erasmo Meoz
Cúcuta, Colombia
Universitas Sumatera Utara
Medan, Indonesia
Hospital Queen Elizabeth II, Sabah
Kota Kinabalu, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Malaysia
National Academy of Medical Sciences/Bir Hospital
Kathmandu, Nepal
Sukraraj Tropical and Infectious Disease Hospital
Kathmandu, Nepal
Hospital Regional de Loreto
Iquitos, Peru
San Lazaro Hospital
Manila, Philippines
Siriraj Hospital, Mahidol University
Bangkok, Thailand
Prince of Songkla University in Southern Thailand
Songkhla, Thailand
Hospital for Tropical Diseases
Ho Chi Minh City, Vietnam
Number 2 Children's Hospital
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.